Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/III open-label intraputaminal VGN-R09b gene therapy study in severe AADC deficiency
CTR20241839Phase 3Active
- Sponsor
- T-MAXESTATE
- Start
- Jul 2024
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of VGN-R09b in Aromatic L-amino acid decarboxylase deficiency (AADC), sponsored by T-MAXESTATE. Started Jul 2024; status: active.
02
Drugs
VGN-R09b
03
Conditions
Aromatic L-amino acid decarboxylase deficiency (AADC)
Beyond the preview
Go deeper on CTR20241839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241839.